Lessee’s Due Diligence Sample Clauses

Lessee’s Due Diligence. Prior to entering into this Lease, the Lessee, in the exercise of due diligence, has made a thorough, independent examination of the Premises and all matters relevant to the Lessee’s decision to enter into this Lease, and the Lessee is thoroughly familiar with all aspects of the Premises and is satisfied that they are in an acceptable condition and meet the Lessee’s needs.
AutoNDA by SimpleDocs
Lessee’s Due Diligence. From the Effective Date at Lessee’s sole expense, Lessee and its Permittees have the right to enter upon Lease Area to conduct and perform soil borings, drainage testing, material sampling, and other geological or engineering tests or studies of Lease Area and Lease Area (collectively, the “Tests”); (iii) to apply for and obtain licenses, permits, approvals, or other relief required or deemed necessary or appropriate for Lessee’s use of Lease Area including, applications for zoning variances, zoning ordinances, amendments, special use permits, and construction permits (collectively, the "Government Approvals"); (iv) to initiate, order and/or schedule utilities; and (v) otherwise to do those things on or off Lease Area that, in the sole discretion, opinion or judgment of Lessee, are necessary or desirable to determine the physical condition of Lease Area, the environmental history of Lease Area, State’s title to Lease Area and the feasibility or suitability of Lease Area for Lessee’s use of Lease Area for a Communications Site. Lessee will not be liable to State or any third party on account of any pre-existing defect or condition on or with respect to Lease Area, regardless of whether such defect or condition is disclosed by Lessee’s inspection. The Testing Period shall conclude upon completion of tests or the start of construction, whichever comes first. At the conclusion of the Testing Period, to the extent Lessee may alter or damage Lease Area as a result of its activities on Lease Area during the Testing Period, Lessee will restore Lease Area to its condition as it existed at the Effective Date, reasonable wear and tear and casualty not caused by Lessee excepted. Subject to the foregoing, Lessee shall indemnify, defend and hold State harmless from and against any and all injury, loss, damage or claims arising directly out of or as a result of Lessee conducting the Tests and its entry onto Lease Area during the Testing Period. If after performing the Tests and examinations noted above, Lessee determines that Lease Area is not suitable for Lessee’s intended use, Lessee may terminate this Lease and have no further obligation to State.
Lessee’s Due Diligence. Prior to entering into this Lease, Xxxxxx has made a thorough, independent examination of the Premises and all matters relevant to Xxxxxx's decision to enter into this Lease, and Xxxxxx is thoroughly familiar with all aspects of the Premises and is satisfied that they are in an acceptable condition and meet Xxxxxx's needs. Without in any way limiting the generality of the foregoing, Xxxxxx's inspection and review has included, to the extent that Lessee in its sole discretion has deemed necessary or appropriate:
Lessee’s Due Diligence 

Related to Lessee’s Due Diligence

  • Due Diligence During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during normal business hours and at the Company’s principal offices, as the Agent may reasonably request from time to time.

  • Diligence After the exercise of the Inhaled Option or Liquidia Respiratory Option, as applicable, GSK shall use Commercially Reasonable Efforts to develop and seek Regulatory Approval in the Territory, for the Liquidia Respiratory Product and Research Products in the applicable Exercised Field(s). Without limiting the foregoing, if GSK exercises the Inhaled Option and fails to initiate any Clinical Trial on at least [***] Research Product in Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. the Inhaled Field within six (6) years after the Effective Date (such event, a “Development Delay”), GSK shall provide Liquidia with a written explanation of the Development Delay for the applicable Research Products. If the Development Delay was not caused solely or primarily for valid scientific reasons (which would include issues with respect to safety and efficacy as well as delays due to feedback from Regulatory Authorities, whether related to the PRINT Material used in the Research Product or the GSK Material contained in the Research Product), then Liquidia shall have the right, but not the obligation, to convert the Inhaled License to a non-exclusive license upon written notice to GSK; provided, that conversion of the Inhaled License to non-exclusive shall be Liquidia’s sole and exclusive remedy in the event of a Development Delay and Liquidia shall not have the right to terminate this Agreement in accordance with Section 15.3; and provided, further that if the Development Delay is caused by the failure of Liquidia or its contract manufacturer to provide GSK with its required supply of PRINT Materials or Research Products then Liquidia shall not have the right to convert the Inhaled License to non-exclusive. In addition, and notwithstanding anything to the contrary, GSK’s obligation to use Commercially Reasonable Efforts is agreed by the Parties to be dependent upon GSK’s timely receipt of GSK’s requirements of viable PRINT Materials or Research Products that meet all applicable specifications agreed to by the Parties and/or Liquidia’s third party contract manufacturer. Any failure to timely deliver PRINT Materials or Research Products to GSK as described above by Liquidia or a third party contract manufacturer, and any subsequent delays or modifications to GSK’s development plans with respect to any Research Product resulting from such failure to supply shall not be deemed to be GSK’s failure to use Commercially Reasonable Efforts under this Section 6.2.

Time is Money Join Law Insider Premium to draft better contracts faster.